Why the study?
Melatonin and nitric oxide critically interact in the central nervous system, prompting a review of this interplay and its involvement in stroke pathophysiology.
Does melatonin improve outcomes in animal models of ischemic stroke through modulation of nitric oxide?
Does melatonin improve outcomes in animal models of ischemic stroke through modulation of nitric oxide?
Melatonin exhibits neuroprotective properties in ischemic stroke models by favorably modulating the nitric oxide pathway, highlighting its therapeutic potential.
Suggests melatonin-NO synergy in stroke neuroprotection; leaves open translation from animal models to clinical use.
This work reviews the complex interplay between melatonin and nitric oxide (NO) in the central nervous system (CNS), with a detailed focus on its involvement in stroke pathophysiology. Melatonin, a neurohormone with potent antioxidant, anti-inflammatory, and neuroprotective properties, and NO, a gaseous signaling molecule with diverse roles, interact crucially. In the context of ischemic stroke, NO exhibits a dual role: it can be neuroprotective (primarily via endothelial nitric oxide synthase (eNOS)) or neurotoxic (especially through inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS), contributing to the formation of damaging peroxynitrite (ONOO−)). Melatonin has consistently demonstrated neuroprotective effects in animal models of stroke. Its key mechanisms related to NO include (1) differential modulation of nitric oxide synthase isoforms, suppressing detrimental iNOS expression/activity while often preserving or enhancing beneficial eNOS; (2) direct scavenging of NO and, critically, highly reactive peroxynitrite, thereby attenuating nitrosative stress; (3) reduction in neuroinflammation, partly by promoting M2 (anti-inflammatory) microglia polarization; and (4) mitochondrial protection and decreased apoptosis. These multifaceted actions of melatonin contribute to reduced infarct volume and improved functional outcomes, underscoring its considerable therapeutic potential for ischemic stroke through the favorable modulation of the melatonin–NO axis.
No takes yet. Share an insight, caveat, or question.
Blanco et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: